Loading clinical trials...

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A ) | Clinical Trials | Clareo Health

COMPLETED

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease Clinical and Biological Outcomes in Patients at Cardiovascular and Thromboembolic Risk

NCT07390604•Centre Hospitalier Régional Metz-Thionville

View on ClinicalTrials.gov

Summary

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

Detailed Description

The biological and clinical outcomes related to Lipoprotein-apheresis DFPP treatment and the associated cardiovascular and thromboembolic events will be described in these patients. Additionally, the impact of DFPP on biological and clinical markers including LDL cholesterol, triglycerides, fibrinogen, hemoglobin, platelet count, C-reactive protein (CRP), blood pressure, plasma volume treated, volume of albumin substitution, volume of plasma rejected, and duration of each Lipoprotein-apheresis DFPP session will be evaluated .

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management

Exclusion Criteria

•-Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy
•Patients presenting with hemodynamic instability
•Patients presenting with acute kidney diseases.

Locations (1)

CHR Metz-Thionville Hopital de Mercy

Metz, France

Key Dates

Start Date

July 1, 2025

Primary Completion Date

September 30, 2025

Completion Date

December 31, 2025

Last Updated

February 5, 2026

Enrollment

ACTUAL participants

Conditions

Lipoprotein(a)Lipoprotein-apheresisDouble-filtration PlasmapheresisHemodialysis ComplicationEnd Stage Chronic Renal Failure

Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians

NCT06420817

Lifestyle Risk ReductionCholesterol, Elevated+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions